{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T09:08:54Z","timestamp":1778404134123,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,10]]},"DOI":"10.7759\/cureus.108579","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T08:37:55Z","timestamp":1778402275000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of Phosphorus-32 Microparticles for Downstaging Locally Advanced Pancreatic Cancer to Resection: A Case Report"],"prefix":"10.7759","author":[{"given":"Fernando","family":"Pereira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Juez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Peiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Guardiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Covadonga","family":"del Riego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Haro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent A","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011, 378:607-20. 10.1016\/S0140-6736(10)62307-0","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2017.105","article-title":"The role of consolidation chemoradiotherapy in locally advanced pancreatic cancer receiving chemotherapy: an updated systematic review and meta-analysis","volume":"50","author":"Chang JS","year":"2018","unstructured":"Chang JS, Chiu YF, Yu JC, Chen LT, Ch'ang HJ. The role of consolidation chemoradiotherapy in locally advanced pancreatic cancer receiving chemotherapy: an updated systematic review and meta-analysis. Cancer Res Treat. 2018, 50:562-74. 10.4143\/crt.2017.105","journal-title":"Cancer Res Treat"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrad137","article-title":"Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2)","volume":"7","author":"Farnes I","year":"2023","unstructured":"Farnes I, Kleive D, Verbeke CS, et al.. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2). BJS Open. 2023, 7:zrad137. 10.1093\/bjsopen\/zrad137","journal-title":"BJS Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy T","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, et al.. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023, 34:987-1002. 10.1016\/j.annonc.2023.08.009","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer PJ Sr","year":"2011","unstructured":"Loehrer PJ Sr, Feng Y, Cardenes H, et al.. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011, 29:4105-12. 10.1200\/JCO.2011.34.8904","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-020-00767-1","article-title":"Endoscopic ultrasound-guided treatment of pancreatic cancer","volume":"22","author":"Cazacu IM","year":"2020","unstructured":"Cazacu IM, Singh BS, Saftoiu A, Bhutani MS. Endoscopic ultrasound-guided treatment of pancreatic cancer. Curr Gastroenterol Rep. 2020, 22:27. 10.1007\/s11894-020-00767-1","journal-title":"Curr Gastroenterol Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-995476","article-title":"Endoscopic ultrasonography-guided interstitial implantation of iodine 125-seeds combined with chemotherapy in the treatment of unresectable pancreatic carcinoma: a prospective pilot study","volume":"40","author":"Jin Z","year":"2008","unstructured":"Jin Z, Du Y, Li Z, Jiang Y, Chen J, Liu Y. Endoscopic ultrasonography-guided interstitial implantation of iodine 125-seeds combined with chemotherapy in the treatment of unresectable pancreatic carcinoma: a prospective pilot study. Endoscopy. 2008, 40:314-20. 10.1055\/s-2007-995476","journal-title":"Endoscopy"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-925253","article-title":"Endoscopic ultrasound-guided interstitial brachytherapy of unresectable pancreatic cancer: results of a pilot trial","volume":"38","author":"Sun S","year":"2006","unstructured":"Sun S, Xu H, Xin J, Liu J, Guo Q, Li S. Endoscopic ultrasound-guided interstitial brachytherapy of unresectable pancreatic cancer: results of a pilot trial. Endoscopy. 2006, 38:399-403. 10.1055\/s-2006-925253","journal-title":"Endoscopy"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100356","article-title":"Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine\/nab-paclitaxel or FOLFIRINOX chemotherapy","volume":"7","author":"Ross PJ","year":"2022","unstructured":"Ross PJ, Wasan HS, Croagh D, et al.. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine\/nab-paclitaxel or FOLFIRINOX chemotherapy. ESMO Open. 2022, 7:100356. 10.1016\/j.esmoop.2021.100356","journal-title":"ESMO Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero MA","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, et al.. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021, 19:439-57. 10.6004\/jnccn.2021.0017","journal-title":"J Natl Compr Canc Netw"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5244-2","article-title":"Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer","volume":"19","author":"Blomstrand H","year":"2019","unstructured":"Blomstrand H, Scheibling U, Bratth\u00e4ll C, Green H, Elander NO. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer. 2019, 19:40. 10.1186\/s12885-018-5244-2","journal-title":"BMC Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13353-2","article-title":"FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review","volume":"30","author":"Eshmuminov D","year":"2023","unstructured":"Eshmuminov D, Aminjonov B, Palm RF, et al.. FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review. Ann Surg Oncol. 2023, 30:4417-28. 10.1245\/s10434-023-13353-2","journal-title":"Ann Surg Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30327-9","article-title":"Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study","volume":"5","author":"Philip PA","year":"2020","unstructured":"Philip PA, Lacy J, Portales F, et al.. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020, 5:285-94. 10.1016\/S2468-1253(19)30327-9","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2025.04.054","article-title":"Combined phosphorus-32 implantation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer: a propensity score-weighted landmark analysis","volume":"103","author":"Lim AH","year":"2026","unstructured":"Lim AH, Nitchingham D, Bednarz J, et al.. Combined phosphorus-32 implantation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer: a propensity score-weighted landmark analysis. Gastrointest Endosc. 2026, 103:126-35.e5. 10.1016\/j.gie.2025.04.054","journal-title":"Gastrointest Endosc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002753","article-title":"Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection","volume":"270","author":"Gemenetzis G","year":"2019","unstructured":"Gemenetzis G, Groot VP, Blair AB, et al.. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019, 270:340-7. 10.1097\/SLA.0000000000002753","journal-title":"Ann Surg"},{"key":"ref16","article-title":"Comparison of resected vs. non-resected PanCO study patients with unresectable locally advanced pancreatic cancer (uLAPC) receiving 32P-microparticles and chemotherapy","volume":"25","author":"Ross PJ","year":"2023","unstructured":"Ross PJ, Burnett D, Nikfarjam M, et al.. Comparison of resected vs. non-resected PanCO study patients with unresectable locally advanced pancreatic cancer (uLAPC) receiving 32P-microparticles and chemotherapy. HPB. 2023, 25:S412.","journal-title":"HPB"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04165-2","article-title":"The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis","volume":"86","author":"Ye C","year":"2020","unstructured":"Ye C, Sadula A, Ren S, Guo X, Yuan M, Yuan C, Xiu D. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis. Cancer Chemother Pharmacol. 2020, 86:731-40. 10.1007\/s00280-020-04165-2","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/461662-use-of-phosphorus-32-microparticles-for-downstaging-locally-advanced-pancreatic-cancer-to-resection-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T08:37:56Z","timestamp":1778402276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/461662-use-of-phosphorus-32-microparticles-for-downstaging-locally-advanced-pancreatic-cancer-to-resection-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.108579","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,10]]}}}